National trends in treatment of type 2 diabetes mellitus, 1994-2007
about
Sulfonylurea versus metformin monotherapy in patients with type 2 diabetes: a Cochrane systematic review and meta-analysis of randomized clinical trials and trial sequential analysisComparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinationsPlace of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: A consensus statementModulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospectsDiscovering Multi-Scale Co-Occurrence Patterns of Asthma and Influenza with Oak Ridge Bio-Surveillance ToolkitQuantifying the Effect of Metformin Treatment and Dose on Glycemic ControlUsing observational data to inform the design of a prospective effectiveness study for a novel insulin delivery deviceHealthcare utilization of people with type 2 diabetes in Germany: an analysis based on health insurance data.Income-related differences in mortality among people with diabetes mellitusCosts and consequences associated with newer medications for glycemic control in type 2 diabetes.Changes in glitazone use among office-based physicians in the U.S., 2003-2009.Use of cystatin C to inform metformin eligibility among adult veterans with diabetes.Current therapies and emerging drugs in the pipeline for type 2 diabetes.Potential therapeutic benefits of strategies directed to mitochondria.National trends in US hospital admissions for hyperglycemia and hypoglycemia among Medicare beneficiaries, 1999 to 2011.Initial and subsequent therapy for newly diagnosed type 2 diabetes patients treated in primary care using data from a vendor-based electronic health record.Genetic variants in transcription factors are associated with the pharmacokinetics and pharmacodynamics of metformin.Ambulatory treatment of type 2 diabetes in the U.S., 1997-2012.Changes in oral antidiabetic prescriptions and improved glycemic control during the years 2002-2011 in Japan (JDDM32).Incretins: clinical perspectives, relevance, and applications for the primary care physician in the treatment of patients with type 2 diabetes mellitusTrends in diabetes medication use and prevalence of geriatric syndromes in older Mexican Americans from 1993/1994 to 2004/2005The "cost" of treating to target: cross-sectional analysis of patients with poorly controlled type 2 diabetes in Australian general practiceComparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort studyReal-world utilization patterns and outcomes of colesevelam hcl in the ge electronic medical record.A novel approach to quality improvement in a safety-net practice: concurrent peer review visitsManagement of type 2 diabetes and its prescription drug cost before and during the economic crisis in Greece: an observational study.Cost implications to health care payers of improving glucose management among adults with type 2 diabetesPPARγ: a molecular link between systemic metabolic disease and benign prostate hyperplasia.Racial ethnic differences in type 2 diabetes treatment patterns and glycaemic control in the Boston Area Community Health SurveyKidney disease in people with diabetes: the expanding epidemic.Metformin exerts anticancer effects through the inhibition of the Sonic hedgehog signaling pathway in breast cancer.Group Medical Visits (GMVs) in primary care: an RCT of group-based versus individual appointments to reduce HbA1c in older peopleSulfonylurea use and the risk of hospital readmission in patients with type 2 diabetes.Geographic variation in pharmacotherapy decisions for U.S. Medicare enrollees with diabetes.Metformin therapy and prostate cancer risk: a meta-analysis of observational studies.National Trends in Ambulatory Oral Anticoagulant Use.Universal drug coverage and socioeconomic disparities in major diabetes outcomesFalsification Testing of Instrumental Variables Methods for Comparative Effectiveness ResearchHealth-Care Costs, Glycemic Control and Nutritional Status in Malnourished Older Diabetics Treated with a Hypercaloric Diabetes-Specific Enteral Nutritional Formula.The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin.
P2860
Q22241119-DA6F814A-4BC8-4D89-AB74-CC49FD1C6770Q22241134-CC998720-BB38-43A9-A607-9EE81FD62FA7Q26783199-1569A4D0-90AA-470F-8528-A5B932DAE117Q26829098-0DF608DB-FC99-40C7-8516-B565E5B0B2CAQ28384821-72BFBA37-2F06-4FAB-B5AF-3B5A5DE642EEQ29038351-46FC3A60-0E43-4DE9-BE62-698F968B3190Q30671559-AB8580FF-C236-4545-A0FA-18F976341E3FQ30911778-48F796DA-31D9-4603-B26D-8703A1C213DFQ33575509-CF1347AA-09AD-4BCF-9C33-1D94ACB2C3CEQ33751401-797EBFA8-8651-4AEE-B645-EABC8949FEA0Q33751542-07F0787C-6A22-4582-9ABB-8BB3798A699DQ33778097-8BF86D22-6F0E-42C0-96F7-5F54E388491BQ33928941-EDA2A95B-2CC4-4D7C-B438-4F53A86C3BF3Q34117168-F5F018CE-3A81-4F06-AE72-7D691A1484A5Q34122776-1ECE03A7-E418-4C3B-B551-2215CF0C835EQ34129085-62789A21-9C84-49B0-8343-86AE5351DB85Q34224429-F56FAC42-9B9C-402C-AA36-C0C86D94B110Q34259412-4C8345F7-A2DE-4CCE-B0CB-AF8A364D375EQ34299670-1CC69D96-BAB0-4270-989B-11F4F8DA9A8EQ34374350-BFE18087-DFE3-4C87-9E19-2B11BEF2F3A3Q34546861-8D71BDE7-5615-46B0-8879-5A60E3156FE3Q34627590-9A524D49-425E-434B-88CB-DDC53E82E114Q34644993-7B9379D3-D62B-4593-8661-A8D0032D7029Q34833895-35F20677-E31D-47E5-839A-649CF1C61948Q35070277-3CBD14F4-EE2F-4150-AF6C-31BEBC42852CQ35110368-FD741BDC-D4DE-4339-BAED-254D45A2BE4DQ35190998-AA41DF5B-FE31-4F43-94A0-32A1EBE6F5BFQ35216293-B1EE01B6-B005-4603-90D5-C97D46D8B4E8Q35604695-FECADC5D-3B97-4F0A-80FA-FC1C6B196950Q35785967-26C4DE0C-83FC-449D-966B-954784A81B86Q35827623-3818F7B5-711E-47BA-9E17-FBB9EEF3D2F7Q35884897-63C816F5-9BE9-4EC0-B817-E4B72A9FAC21Q35898272-3DD2B9D6-5AC6-42DC-8F49-1458A09E8628Q36098838-DF488007-85BA-4370-8E4A-1B85633DDC5FQ36182935-3D464608-98F6-43E3-994C-BD082182578AQ36315659-CD9DA50A-2F5A-4831-AAA8-85ABAF5EBC6EQ36334609-897B6799-1421-46BD-9070-6EA5E1A3A574Q36706682-C50B755F-1A5F-47F0-943E-21D0AB14DDA2Q36732106-01874694-CB53-4F65-A082-9ABA838A185AQ36899802-EA813815-3A8C-4B5F-BEE5-E02D79422505
P2860
National trends in treatment of type 2 diabetes mellitus, 1994-2007
description
2008 nî lūn-bûn
@nan
2008 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
name
National trends in treatment of type 2 diabetes mellitus, 1994-2007
@ast
National trends in treatment of type 2 diabetes mellitus, 1994-2007
@en
National trends in treatment of type 2 diabetes mellitus, 1994-2007
@nl
type
label
National trends in treatment of type 2 diabetes mellitus, 1994-2007
@ast
National trends in treatment of type 2 diabetes mellitus, 1994-2007
@en
National trends in treatment of type 2 diabetes mellitus, 1994-2007
@nl
prefLabel
National trends in treatment of type 2 diabetes mellitus, 1994-2007
@ast
National trends in treatment of type 2 diabetes mellitus, 1994-2007
@en
National trends in treatment of type 2 diabetes mellitus, 1994-2007
@nl
P2093
P2860
P3181
P1476
National trends in treatment of type 2 diabetes mellitus, 1994-2007
@en
P2093
G Caleb Alexander
Niraj L Sehgal
Rachael M Moloney
Randall S Stafford
P2860
P304
P3181
P356
10.1001/ARCHINTE.168.19.2088
P407
P577
2008-10-27T00:00:00Z